Omalizumab, sold under the branded name Xolair, was first approved by the FDA in 2003 as an asthma treatment aimed at improving moderate and severe asthma. It has since been approved in both ...

Omalizumab is indicated for adults and adolescents with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are ...

Objectives: To describe allergic asthma and allergic rhinitis pathophysiology and review the pharmacologic, pharmacokinetic, pharmacodynamic, efficacy, and safety data for omalizumab. Methods ...

A man's orgasms triggered flu-like symptoms and brain fog due to a rare condition called post-orgasmic illness syndrome .

The product Xolair has a history that goes back several decades. It was originally approved in 2003 for the treatment of moderate to severe asthma. The drug was subsequently granted marketing ...

Join MIMS now and pay nothing for the first 30 days Join GPOnline now and pay nothing for the first 30 days ...

Certain medical therapies may help someone outgrow asthma, especially newer biologics such as Xolair (omalizumab). In many ...

Britain’s National Institute for Health and Clinical Excellence (NICE) has decided to withdraw its recommendation for asthma drug, Xolair, citing that a review of up-to-date clinical trial data ...

The FDA has approved a new prefilled syringe formulation for Roche’s asthma drug Xolair, as the Swiss company aims to prolong its shelf life. Xolair (omalizumab) generated revenues of more than ...

The Phase 2 trial in asthma is primarily focused on PK and PD profiles compared to omalizumab to help inform dosing for a potential Phase 3 registrational trial. Jemincare expects to have topline ...